Langerhans cell histiocytosis: a comprehensive review

Pathology

Volumn 47, Issue 4, 2015, Pages 294-301

  Demellawy, Dina El ^a,b   Young, James Lee ^a   Nanassy, Joseph De ^a,b   Chernetsova, Elizaveta ^a   Nasr, Ahmed ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

BRAF; BRAF V600E; Erdheim Chester disease; Langerhans cell histiocytosis; MAPK; pulmonary Langerhans cell histiocytosis; RAF; RAS

Indexed keywords

HUMAN; LANGERHANS CELL HISTIOCYTOSIS;

HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS;

EID: 84978759441     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000256     Document Type: Article

References (120)

1. 1. Filipovich, A., McClain, K., Grom, A., Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant, 16, 2010, S89.
2. 2. Campo, E., Swerdlow, S., Harris, N., et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117 (2011), 5019–5032.
3. 3. Langerhans, P., Uber die nerven der menschlichen haut. Arch Pathol Anat 44 (1868), 325–337 (German.).
4. 4. Smith, T., Skull cap showing congenital deficiency of bone. Trans Pathol Soc London 16 (1865), 224–225.
5. 5. Letterer, E., Aleukamische retikulose (ein Beitrag zu den proliferativen Erkrankungen des Retikuloendothelialapparates). Frankfurter Zeitschritte der Pathology 30 (1924), 377–394 (German.).
6. 6. Siwe, S., Die reticuloendotheliose – ein neues krankheitsbild unter den hepatosplenomegalien. Zeitschrift Fur Kinderheilkunde 55 (1933), 212–247 (German.).
7. 7. Otani, S., Ehrlich, J., Solitary granuloma of bone, simulating primary neoplasm. Am J Pathol 16 (1940), 479–490.
8. 8. Lichtenstein, L., Jaffe, H., Eosinophilic granuloma of bone. Am J Pathol 16 (1940), 595–604.
9. 9. Coppes-Zantigna, A., Egeler, R., Historical review. The Langerhans cell histiocytosis X files revealed. Br J Haematol 116 (2002), 3–9.
10. 10. Lichtenstein, L., Histiocytosis X: integration of eosinophilic granuloma of bone, Letterer-Siwe Disease and Schuller-Christian. Disease as related manifestations of a single nosologic entity. Am Med Assoc Arch Pathol 56 (1953), 84–102.
11. 11. Birbeck, M., Breathnach, A., Everall, J., An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo. J Invest Dermatol 37 (1961), 51–63.
12. 12. Hashimoto, K., Pritzker, M.S., Electron microscopic study of reticulohistiocytoma: an unusual case of congenital self-healing reticulohistiocytosis. Arch Dermatol 107 (1973), 263–270.
13. 13. Risdall, R.J., Dehner, L.P., Duray, P., et al. Histiocytosis X (Langerhans’ cell histiocytosis). Prognostic role of histopathology. Arch Pathol Lab Med 107 (1983), 59–63.
14. 14. Egeler, R.M., Favara, B.E., van Meurs, M., et al. Differential in situ cytokine proles of Langerhans-like cells and T-cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94 (1999), 4195–4201.
15. 15. Geissmann, F., Lepelletier, Y., Fraitag, S., et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 971 (2001), 1241–1284.
16. 16. Davies, H., Bignell, G.R., Cox, C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
17. 17. Manz, M.G., Miyamoto, T., Akashi, K., et al. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 99 (2002), 11872–11877.
18. 18. Caux, C., Dezutter-Dambuyant, C., Schmitt, D., Banchereau, J., GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360 (1992), 258–261.
19. 19. Ginhoux, F., Merad, M., Ontogeny and homeostasis of Langerhans cells. Immunol Cell Biol 88 (2010), 387–392.
20. 20. Merad, M., Manz, M.G., Karsunky, H., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3 (2002), 1135–1141.
21. 21. Kaplan, D.H., Jenison, M.C., Saeland, S., et al. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 23 (2005), 611–620.
22. 22. Chorro, L., Sarde, A., Li, M., et al. Langerhans cell proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network. J Exp Med 206 (2009), 3089–3100.
23. 23. Chen, W., Wang, J., Wang, E., et al. Detection of clonal lymphoid receptor gene rearrangements in Langerhans cell histiocytosis. Am J Surg Pathol 34 (2010), 1049–1057.
24. 24. Romani, N., Clausen, B.E., Stoitzner, P., Langerhans cells and more: Langerin-expressing dendritic cell subsets in the skin. Immunol Rev 234 (2010), 120–141.
25. 25. Geissmann, F., Prost, C., Monnet, J.P., et al. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood mono-cytes into dendritic Langerhans cells. J Exp Med 187 (1998), 961–966.
26. 26. Ito, T., Inaba, M., Inaba, K., et al. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol 163 (1999), 1409–1419.
27. 27. Dzionek, A., Fuchs, A., Schmidt, P., et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165 (2000), 6037–6046.
28. 28. Martínez-Cingolani, C., Grandclaudon, M., Jeanmougin, M., et al. Human blood BDCA-1 dendritic cells differentiate into Langerhans-like cells with thymic stromal lymphopoietin and TGF-β. Blood 124 (2014), 2411–2420.
29. 29. Tazi, A., Mareau, J., Bergeron, A., et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenviroment. J Immunol 163 (1999), 3511–3515.
30. 30. Amir, G., Weintraub, M., Association of cell cycle-related gene products and NF-kappaB with clinical parameters in Langerhans cell histiocytosis. Pediatr Blood Cancer 50 (2008), 304–307.
31. 31. Martin-Duverneuil, N., ldbaih, A., Huong-Xuan, K., et al. MRI features of degenerative Langerhans cell histiocytosis. Eur Radiol 16 (2006), 2074–2082.
32. 32. Fleming, M.D., Pinkus, J.L., Fournier, M.V., et al. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood 101 (2003), 2473–2475.
33. 33. Badalian-Very, G., Vergilio, J.A., Fleming, M., et al. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol 8 (2013), 1–20.
34. 34. Willman, C., Busque, L., Griffith, B., et al. Langerhans’ cell histiocytosis (histiocytosis X)±aclonal proliferatice disease. N Eng J Med 331 (1994), 154–160.
35. 35. Scappaticci, S., Danesino, C., Rossi, E., et al. Cytogenetic abnormalities in PHA-stimulated lymphocytes from patients with Langerhans cell histocytosis. Br J Haematol 111 (2000), 51–258.
36. 36. Betts, D., Leibundgut, K., Feldges, A., et al. Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer 77 (1998), 552–555.
37. 37. Egeler, R.M., Neglia, J.P., Puccetti, D.M., et al. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer 71 (1993), 865–873.
38. 38. Human Genome Variation Society (HGVS). Nomenclature for the description of sequence variants. Mar 2014, cited Sep 2014. http://www.hgvs.org/mutnomen/.
39. 39. Bouzourene, H., Hutter, P., Losi, L., et al. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Familial Cancer 9 (2010), 167–172.
40. 40. My Cancer Genome. BRAF c.1799T>A (V600E) mutation in melanoma. Cited Sep 2014. http://www.mycancergenome.org/content/disease/mela-noma/braf/54/.
41. 41. Hilger, R., Scheulen, M., Strumberg, D., The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25 (2002), 511–518.
42. 42. Prince, M.H., Identifying mutant pathways in the histiocytoses. Blood 124 (2014), 2901–2903.
43. 43. Wellbrock, C., Karasarides, M., Marais, R., The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5 (2005), 875–885.
44. 44. Badalian-Very, G., Vergilio, J.A., Degar, B.A., et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116 (2010), 1919–1923.
45. 45. Chakraborty, R., Hampton, O.A., Shen, X., et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124 (2014), 3007–3015.
46. 46. Mercer, K., Giblett, S., Green, S., et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65 (2005), 11493–11500.
47. 47. Berres, M.L., Salmon, H., Peters, T., et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med, 211, 2014, 669.
48. 48. Sahm, F., Capper, D., et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 120 (2012), e28–e34.
49. 49. Go, H., Jeon, Y., Huh, J., et al. Frequent detection of BRAFV 600E mutations in histiocytic and dendritic cell neoplasms. Histopathology 65 (2014), 261–272.
50. 50. Wei, R., Wang, Z., Li, X., et al. Frequent BRAF V600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis. Biomed Rep 1 (2013), 365–368.
51. 51. Satoh, T., Smith, A., Sarde, A., et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One, 7, 2012, e33891.
52. 52. Badalian-Very, G., Vergilio, J.A., Degar, B.A., et al. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol 156 (2012), 163–172.
53. 53. Nelson, D., Quispel, W., Badalian-Very, G., et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123 (2014), 3152–3155.
54. 54. Haroche, J., Charlotte, F., Arnaud, L., et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120 (2012), 2700–2703.
55. 55. Emile, J-F, Diamond, E.L., Helias-Rodzewicz, Z., et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 124 (2014), 3016–3019.
56. 56. Diamond, E.L., Abdel-Wahab, O., Pentsova, E., et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood 122 (2013), 1089–1091.
57. 57. Roden, A.C., Hu, X., Kip, S., et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 38 (2014), 548–551.
58. 58. Machnicki, M., Stoklosa, T., BRAF - A new player in hematological neoplasms. Blood Cells Mol Dis 53 (2014), 77–83.
59. 59. Chilosi, M., Facchetti, F., Calió, A., et al. Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. Leuk Lymphoma 55 (2014), 2620–2626.
60. 60. Berres, M.L., Allen, C.E., Merad, M., Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. Adv Immunol 120 (2013), 127–161.
61. 61. Brown, N.A., Furtado, L.V., Betz, B.L., et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E negative Langerhans cell histiocytosis. Blood 124 (2014), 1655–1658.
62. 62. Grana, N., Langerhans cell histiocytosis. Cancer Control 21 (2014), 328–334.
63. 63. Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
64. 64. Dietrich, S., Glimm, H., Andrulis, M., et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366 (2012), 2038–2040.
65. 65. Haroche, J., Cohen-Aubart, F., Emile, J.F., et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121 (2013), 1495–1500.
66. 66. Emery, C.M., Vijayendran, K.G., Zipser, M.C., et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106 (2009), 20411–20416.
67. 67. Arico, M., Nichols, K., Whitlock, J.A., et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol 107 (1999), 883–888.
68. 68. De Chadarevian, J.P., Pawel, B.R., Hereditary Langerhans cell histiocytosis: Instances of apparent vertical transmission. Med Pediatr Oncol, 31, 1998, 559.
69. 69. Huang, F., Arceci, R., The histiocytoses of infancy. Semin Perinatol 23 (1999), 319–331.
70. 70. Guyot-Goubin, A., Donadieu, J., Barkaoui, M., et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer 51 (2008), 71–75.
71. 71. Salotti, J.A., Nanduri, V., Pearce, M.S., et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child 94 (2009), 376–380.
72. 72. Stalemark, H., Laurencikas, E., Karis, J., et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 51 (2008), 76–81.
73. 73. Broadbent, V., Gadner, H., Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 12 (1998), 327–328.
74. 74. Lau, L., Krafchik, B., Trebo, M., Weitzman, S., Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 46 (2006), 66–71.
75. 75. Suri, H.S., Yi, E.S., Nowakowski, G.S., et al. Pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis 19 (2012), 7–16.
76. 76. Munn, S., Chu, A.C., Langerhans’ cell histiocytosis of the skin. Hematol Oncol Clin North Am 12 (1998), 269–286.
77. 77. Zunino-Goutorbe, C., Eschard, C., Durlach, A., Bernard, P., Congential solitary histiocytoma: a variant of Hashimoto-Pritzker histiocytosis. A retrospective study of 8 cases. Dermatology 216 (2008), 118–124.
78. 78. Pujol, R.M., Moreno, A., Lopez, D., et al. Childhood self-healing histiocytosis X. Pediatr Dermatol 5 (1985), 97–102.
79. 79. Esterly, N.B., Maurer, H.S., Gonzalez-Crussi, F., Histiocytosis X: a seven-year experience at a children's hospital. J Am Acad Dermatol 13 (1985), 481–496.
80. 80. Slater, J.M., Swarm, O.J., Eosinophilic granuloma of bone. Med Pediatr Oncol 8 (1980), 151–164.
81. 81. Peng, X.S., Pan, T., Chen, L.Y., et al. Langerhans’ cell histiocytosis of the spine in children with soft tissue extension and chemotherapy. Int Orthop 33 (2009), 731–736.
82. 82. Yousem, S.A., Dacic, S., Nikiforov, Y.E., et al. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using nextgeneration sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 143 (2013), 1679–1684.
83. 83. Vassallo, R., Ryu, J.H., Schroeder, D.R., et al. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis inadults. N Engl J Med 346 (2002), 484–490.
84. 84. Colby, T.V., Lombard, C., Histiocytosis X in the lung. Hum Pathol 14 (1983), 847–856.
85. 85. Travis, W.D., Borok, Z., Roum, J., et al. Pulmonary Langerhans’ cell granulomatosis (histiocytosis X): a clinicopathologic study of 48 cases. Am J Surg Pathol 17 (1993), 971–986.
86. 86. Friedman, P.J., Liebow, A.A., Sokoloff, J., Eosinophilic granuloma of lung: clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore) 60 (1981), 385–396.
87. 87. Egeler, R.M., van Halteren, A.G., Hogendoorn, P.C., et al. Langerhans cell histiocytosis: Fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev 234 (2010), 213–232.
88. 88. Bratke, K., Klug, M., Bier, A., et al. Function-associated surface molecules on airway dendritic cells in cigarette smokers. Am J Respir Cell Mol Biol 38 (2008), 655–660.
89. 89. Merad, M., Ginhoux, F., Collin, M., Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 8 (2008), 935–947.
90. 90. Vassallo, R., Walters, P.R., Lamont, J., et al. Cigarette smoke promotes dendritic cell accumulation in COPD; aLung Tissue Research Consortium study. Respir Res, 11, 2010, 45.
91. 91. Lasek-Duriez, A., Charkaluk, M.L., Gosset, P., Modiano, P., Blueberry muffin baby and Langerhans’ congenital cell histiocytosis. Ann Dermatol Venereol 141 (2014), 130–133.
92. 92. Yousem, S.A., Colby, T.V., Chen, Y.Y., et al. Pulmonary Langerhans’ cell histiocytosis: Molecular analysis of clonality. Am J Surg Pathol 25 (2001), 630–636.
93. 93. Rizzo, F.M., Cives, M., Simone, V., Silvestris, F., New insights into the molecular pathogenesis of Langerhans cell histiocytosis. Oncologist 19 (2014), 151–163.
94. 94. Windebank, K., Nanduri, V., Langerhans cell histiocytosis. Arch Dis Child 94 (2009), 904–908.
95. 95. Hashimoto, K., Griffin, D., Kohsbaki, M., Self-healing reticulohistiocytosis: a clinical, histological and ultrastructural study of the fourth case in the literature. Cancer 49 (1982), 331–337.
96. 96. Chunharas, A., Pabunruang, W., Hongeng, S., Congenital self-healing Langerhans cell histiocytosis with pulmonary involvement:spontaneous regression. J Med Assoc Thai 85 (2002), S1309–S1313.
97. 97. Garcia Muret, M.P., Fernandez-Figueras, M.T., Gonzales, M.J., De Moragas, M.J., Congenitalspontaneously regressive Langerhans cell histiocytosis with bone involvement (eosinophilic granuloma). Ann Dermatol Venereol 122 (1995), 612–614.
98. 98. Whitehead, B., Michaels, M., Sahni, R., et al. Congenital selfhealing histio-cytosis with persistent cellular immunological abnormalities. Br J Dermatol 122 (1990), 563–568.
99. 99. Aggarwal, V., Seth, A., Jain, M., et al. Congenital Langerhans cell histiocytosis with skin and lung involvement: spontaneous regression. Indian J Pediatr 77 (2010), 811–812.
100. 100. Da Costa, C.E., Annels, N.E., Faaij, C.M., et al. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langer-hans cell histiocytosis. J Exp Med 201 (2005), 687–693.
101. 101. Hashimoto, K., Pritzker, M.S., Electron microscopic study of reticulohistio-cytoma: an unusual case of congenital self-healing reticulohistiocytosis. Arch Dermatol 107 (1973), 251–270.
102. 102. Longaker, M.A., Frieden, I.J., LeBoit, P.E., Sherertz, E.F., Congenital “self-healing” Langerhans cell histiocytosis: the need for long-term follow-up. J Am Acad Dermatol 31 (1994), 910–916.
103. 103. Kim, H.K., Park, C.J., Jang, S., et al. Bone marrow involvement of Langerhans cell histiocytosis: immunohistochemical evaluation of bone marrow for CD1a, Langerin, and S 100 expression. Histopathology 65 (2014), 742–748.
104. 104. Xu, X., Liu, W.P., Yang, Q.P., et al. Langerhans cell histiocytosis: a clinico-pathologic and immunohistochemical analysis of 258 cases. Zhonghua Bing Li Xue Za Zhi 41 (2012), 91–96.
105. 105. Mizumoto, N., Takashima, A., CD1a and langerin: Acting as more than Langerhans cell markers. J Clin Invest 113 (2004), 658–660.
106. 106. Merad, M., Ginhoux, F., Collin, M., Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 8 (2008), 935–947.
107. 107. Idoyaga, J., Suda, N., Suda, K., et al. Antibody to Langerin/CD207 localizes large numbers of CD8 alpha1 dendritic cells to themarginal zone of mouse spleen. Proc Natl Acad Sci USA 106 (2009), 1524–1529.
108. 108. Park, H.J., Jeon, Y.K., Lee, A.H., et al. Use of the JL1 epitope, which encompasses the nonglycosylation site of CD43, as a marker of immature/neoplastic Langerhans cells. Am J Surg Pathol 36 (2012), 1150–1157.
109. 109. Galluzzo, M.L., Braier, J., Rosenzweig, S.D., et al. Bone marrow findings at diagnosis in patients with multisystem langerhans cell histiocytosis. Pediatr Dev Pathol 13 (2010), 101–106.
110. 110. Bhattacharjee, P., Glusac, E., Langerhans cell hyperplasia in scabies: a mimic of Langerhans cell histiocytosis. J Cutan Pathol 34 (2007), 716–720.
111. 111. Drut, R., Gomez Peral, C., Garone, A., Rositto, A., Langerhans cell hyperplasia of the skin mimicking Langerhans cell histiocytosis: a report of two cases in children not associated with scabies. Fetal Pediatr Pathol 29 (2010), 231–238.
112. 112. Pigozzi, B., Bordignon, M., Fortina, A.B., et al. Expression of the CD1a molecule in B- and T-lymphoproliferative skin conditions. Oncol Rep 15 (2006), 347–351.
113. 113. Christie, L.J., Evans, A.T., Bray, S.E., et al. Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon. Hum Pathol, 37, 2006, 32.
114. 114. Haroche, J., Arnaud, L., Amoura, Z., Erdheim-Chester disease. Curr Opin Rheumatol 24 (2012), 53–59.
115. 115. Emile, J.F., Wechsler, J., Brousse, N., et al. Langerhans’ cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol 19 (1995), 636–641.
116. 116. Marchal, A., Cuny, J.F., Montagne, K., et al. Associated Langerhans cell histiocytosis and Erdheim-Chester disease. Ann Dermatol Venereol 138 (2011), 743–747.
117. 117. Hervier, B., Haroche, J., Arnaud, L., et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124 (2014), 1119–1126.
118. 118. Ivan, D., Neto, A., Lemos, L., Gupta, A., Erdheim-Chester disease: a unique presentation with liver involvement and vertebral osteolytic lesions. Arch Pathol Lab Med 127 (2003), e337–e339.
119. 119. Veyssier-Belot, C., Cacoub, B., Capparros-Lefebvre, D., et al. Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases. Medicine 75 (1996), 157–169.
120. 120. Kenn, W., Eck, M., Allolio, B., et al. Erdheim-Chester disease: evidence for a disease entity different from Langerhans cell histiocytosis? Three cases with detailed radiological and immunohistochemical analysis. Hum Pathol 31 (2000), 734–739.